文献计量学分析我国双相情感障碍的发展趋势

目的通过分析我国双相情感障碍的文献分布,探讨我国双相情感障碍的发展趋势。方法采用文献计量学方法和MicrosoftExcel技术,通过利用中国生物医学文献数据库中收录的有关以双相情感障碍为主题的文献,从时间分布、单位分布、地域分布、期刊分布、第一作者分布和主要内容等方面,进行多角度文献分析。结果双相情感障碍文献的时间分布、单位分布、地域分布与地区经济发展密切相关;浙江常州全军精神卫生中心解放军第102医院、深圳市精神卫生研究所（深圳市精神卫生中心）、南京医科大学附属脑科医院及在以上单位工作的作者可视为该病的核心研究机构和研究者;《临床精神医学杂志》（6．67％）、《四川精神卫生》（5．14％）、《上海精神医学》（4．72％）、《中国神经精神疾病杂志》（4．16％）可视为该病研究的核心期刊;国内学者对该病的研究主要集中于临床药物治疗、临床诊断、临床病例报告（约占临床研究的61．98％）、流行病学调查（约占预防医学研究的63％）等方面,对于双相情感障碍预防方面（约占论文总数的28．97％）及合并外科疾病围手术期（约占临床研究的4．04％）的专题研究报道较少。结论双相情感障碍研究在国内尚处于初步研究阶段,各地区发展不平衡,对该病的预防和治疗认识不足。各地区应重视该病的防治工作,建立预警机制,制定相应防治措施,防止该病的流行和突发事件的发牛。     

儿童颈动脉内-中膜厚度与肥胖类型相关性的超声评价

目的应用超声手段探测儿童颈动脉内膜-中层厚度（IMT）,探讨其与儿童肥胖类型的关系。方法依体质指数（BMI）、腰围身高比（WHtR）标准,入组外周性肥胖组160名（A组）,内脏性肥胖150名（B组）,正常体重儿童160名（正常对照组）;应用超声手段探测各组儿童内脏脂肪厚度（VFT）和颈动脉内膜-中层厚度,比较3组间各项检测参数。结果内脏肥胖组VFT、IMT均高于外周性肥胖组及正常组,差异具有统计学意义（P〈0.05）;外周性肥胖组VFT、IMT与正常组相似,差异没有显著性。结论IMT与肥胖类型相关,内脏性肥胖儿童VFT、IMT增加。实时超声检查技术为研究儿童肥胖类型提供了一种新的检测手段。     

食管癌切除胸腹二区淋巴结清扫手术疗效的研究

目的：分析总结食管癌切除胸腹二区淋巴结清扫的手术疗效。方法：回顾分析1986年2月～2007年12月我院对中下段食管癌和上段食管癌分别采用Ivor—Lewis术式,即上腹正中、右胸后外侧二切口切除及Akiyama术式．即右胸后外侧、上腹正中、左颈部三切口切除,并作胸腹二区淋巴结清扫治疗胸段食管癌1690例的临床资料,总结胸腹二区淋巴结转移的发生率并随访1、3、5年的生存率。结果：全组手术切除率为97．86％（1690／1727）。全组有淋巴结转移782例,占46．27％,其中胸部淋巴结转移占38．93％（658／1690）,腹部淋巴结转移占25．92％（438／1690）,胸部淋巴结转移发生于最上纵隔位于气管食管沟及喉返神经旁占20．47％（346／1690）,术后共有178例发生230例次各种并发症,总的并发症的发生率为13．6％（230／1690）,其中肺部并发症为第一位,占34．3％,心律失常占17．4％,喉返神经损伤发生率为8．7％,吻合口瘘发生率为1．7％。术后1、3、5年的生存率分别为88．2％（1161／1316）、63．5％（634／998）和51．8％（331／639）。无淋巴结转移的5年生存率为65．2％（219／336）,有淋巴结转移的5年生存率为32．3％（102／316）。结论：Ivor-Lewis术式和Akiyama术式胸腹腔有良好的显露,淋巴结清扫彻底、方便,尤其对右侧最上纵隔沿喉返神经旁淋巴结清扫便利。特别对有淋巴结转移的食管癌患者行胸、腹二区淋巴结清扫十分必要,能明显提高术后5年生存率。     

Decreased external home help use with improved clinical status in rheumatoid arthritis: an exploratory analysis of the Abatacept in Inadequate responders to Methotrexate (AIM) trial

OBJECTIVES: The aims of this study were to examine the relationship between external home help (EHH) use (ie, help provided by someone other than family or friends) and clinical response and patient-reported outcomes in patients with rheumatoid arthritis (RA), and to determine whether abatacept treatment in addition to methotrexate reduces the need for EHH. METHODS: EHH use was recorded monthly in the Abatacept in Inadequate responders to Methotrexate (AIM) trial, a 12-month, randomized, double-blind, placebo-controlled trial of abatacept in patients with active RA also receiving methotrexate. Clinical response was defined using American College of Rheumatology (ACR) criteria, European League Against Rheumatism (EULAR) criteria, and Disease Activity Scale (DAS)-28 score. Patient-reported outcomes included the Health Assessment Questionnaire (HAQ), 100-mm visual analog scales (VASs) for pain and fatigue, and the Medical Outcomes Study 36-item Short Form Health Survey (SF-36) for health-related quality of life. Analysis of covariance and regression analysis were performed to investigate the relationship between change in EHH use and both clinical response and patient-reported outcomes. RESULTS: Of 590 patients enrolled in the study, 232 (39.3%) were receiving EHH at baseline (mean age, 50.2 years; 88% female; 85% white; mean duration of RA, 8.8 years; mean [SD] EHH use, 15.6 [11.3] days). The level of EHH use was consistently higher with poorer scores on the HAQ, pain and fatigue VASs, DAS28, and SF-36. At 12 months, the mean reduction from baseline in EHH use was significantly greater in patients with ACR-50 or ACR-70 clinical response, EULAR good or moderate response, DAS28 remission, and clinically meaningful improvements in patient-reported outcomes. On multiple regression analysis, change in SF-36 Physical Functioning subscale score was the most important contributor to change in EHH after adjustment for other variables. The mean reduction from baseline in EHH use was significantly greater with abatacept compared with placebo over the study period (all, P<0.001). CONCLUSIONS: In this exploratory analysis of data from patients with active RA from the AIM trial, EHH use was decreased significantly with improvements in clinical response, disease activity, and patient-reported outcomes. Treatment with abatacept in addition to methotrexate was associated with significantly decreased EHH use, suggesting that abatacept may have been associated with improved function and increased physical independence in these patients with RA.     

Arthritis symptoms, the work environment, and the future: measuring perceived job strain among employed persons with arthritis

OBJECTIVE: To develop a measure of job strain related to differing aspects of working with arthritis and to examine the demographic, illness, work context, and psychosocial variables associated with it. METHODS: Study participants were 292 employed individuals with osteoarthritis or inflammatory arthritis. Participants were from wave 3 of a 4-wave longitudinal study examining coping and adaptation efforts used to remain employed. Participants completed an interview-administered structured questionnaire, including a Chronic Illness Job Strain Scale (CIJSS) and questions on demographic (e.g., age, sex), illness and disability (e.g., disease type, pain, activity limitations), work context (e.g., job type, job control), and psychosocial variables (e.g., arthritis-work spillover, coworker/managerial support, job perceptions). Principal component analysis and multiple linear regression were used to analyze the data. RESULTS: A single factor solution emerged for the CIJSS. The scale had an internal reliability of 0.95. Greater job strain was reported for future uncertainty, balancing multiple roles, and difficulties accepting the disease than for current workplace conditions. Participants with inflammatory arthritis, more frequent severe pain, greater workplace activity limitations, fewer hours of work, less coworker support, and greater arthritis-work spillover reported greater job strain. CONCLUSION: The findings underscore the diverse areas that contribute to perceptions of job strain and suggest that existing models of job strain do not adequately capture the stress experienced by individuals working with chronic illnesses or the factors associated with job strain. Measures similar to the CIJSS can enhance the tools researchers and clinicians have available to examine the impact of arthritis in individuals' lives.     

酶联免疫吸附试验中HBsAg室内质控参考品的制备和应用

目的建立室内质控参考品以鉴别诊断试剂的质量和控制操作误差,提高乙型肝炎病毒表面抗原的检测准确度。方法以国家标准品为标准制备灵敏度系列参考品、特异性参考品及精密性参考品。检测其稳定性,并进行同厂家、不同批号试剂的比较及不同厂家、三批试剂的比较。结果制备的室内质控参考品在-20℃与4℃保存3～4周检测结果无统计学差异。采用同一厂家、不同批号的HBsAg诊断试剂检测室内质控参考品,结果无统计学差异。采用不同厂家、同一批号的HBsAg诊断试剂检测结果有统计学差异。结论我们建立的室内质控参考品适宜作HBsAg室内质控,提醒我们在更换试剂厂家时应特别注意室内质控参考品的变化。     

Complex and simple coronary artery stenoses: a new way to interpret coronary angiograms based on morphologic features of lesions

For many years, atherosclerotic coronary artery lesions have been described by angiographers only in terms of location and degree of narrowing. However, it has become apparent that coronary stenoses generally have distinct morphologic features that can be recognized at angiography and that allow them to be classified as either "simple" or "complex" plaques. Complex plaques are those characterized by ulcerated or ruptured surfaces, subintimal hemorrhage, superimposed partially occluding thrombi, recanalized thrombi, or some combination. Pathologic studies have shown a very high frequency of these lesions at sites of total thrombotic occlusion of coronary arteries. Clinical and angiographic studies have demonstrated a high frequency of such lesions in living patients with both unstable angina and acute myocardial infarction. The presence of complex stenoses has also been found to increase the risk of future myocardial infarction. Plaque morphology thus appears to significantly affect the prognosis of patients with coronary disease and should be carefully evaluated in interpretation of all coronary angiograms.     

复方土牛膝糖浆剂抗病毒作用的实验研究

目的:观察复方土牛膝糖浆剂在体外和动物模型上的抗病毒作用。方法:用细胞培养法,通过观察细胞病变评价复方土牛膝糖浆剂对常见的致上呼吸道感染的柯萨奇B族病毒4型(CoxB4)、副流感病毒(HVJ)、呼吸道合胞病毒(RSV)、单纯疱疹病毒(HSV-Ⅰ)所致的细胞病变(CPE)的抑制作用;通过用流感病毒滴鼻感染小鼠来研究复方土牛膝糖浆剂对病毒感染小鼠所引起的死亡保护作用。结果:复方土牛膝糖浆在体外对CoxB4、RSV病毒的致细胞病变作用有明显抑制作用,其IC50分别为2.0、2.8μL糖浆/mL,TI分别为5.6和4,对HSV-1、副流感-1型病毒的致细胞病变有一定的抑制作用。其IC50分别为4.0、5.0μL糖浆/mL,TI分别为2.8和2.24。在小鼠感染病毒15天内,复方土牛膝糖浆5mL/(kg.d)剂量组动物的死亡率为55%;死亡保护率分别为38.39%,与感染对照组相比有显著差异(P<0.05),复方土牛膝糖浆10mL/(kg.d)、5mL/(kg.d)两个剂量组小鼠的存活天数较感染组明显延长,与对照组比较有显著性差异。生命延长率分别为17.67%和22.22%。结论:复方土牛膝糖浆剂无论在体内或是体外均有较明显的抗病毒作用。     

息风化痰通腑汤合醒脑静注射液治疗急性脑出血疗效观察

目的观察息风化痰通腑汤合醒脑静治疗急性脑出血的临床疗效。方法将53例中小量脑出血(≤30 ml)患者随机分成2组。治疗组29例在常规西医综合治疗基础上,加用息风化痰通腑汤合醒脑静注射液治疗;对照组24例仅采用常规西医综合治疗。2组均14日为1个疗程,判定疗效。结果:治疗组有效率93.1%,对照组83.3%,2组比较有显著性差异(P<0.05),治疗组疗效显著优于对照组。2组治疗前后昏迷情况比较、血肿吸收情况及神经功能缺损积分对比,均有显著性差异(P<0.01),且治疗组疗效明显优于对照组(P<0.01)。结论息风化痰通腑汤合醒脑静注射液治疗中小量急性脑出血,能提高治愈率,降低病死率,缩短治疗时间,提高生存质量,无明显毒副作用。